These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


156 related items for PubMed ID: 18775272

  • 21. [Use of Cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis].
    Dudzik B, Kaczmarczyk I, Radziszewski A, Sułowicz W.
    Przegl Lek; 2001; 58(7-8):798-804. PubMed ID: 11769390
    [Abstract] [Full Text] [Related]

  • 22. The treatment of relapse in adults with minimal change nephrotic syndrome: myths and facts.
    Shigidi MM.
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):10-7. PubMed ID: 21196608
    [Abstract] [Full Text] [Related]

  • 23. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
    Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A.
    Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
    Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A.
    Kidney Int; 2019 Jan; 95(1):210-218. PubMed ID: 30497684
    [Abstract] [Full Text] [Related]

  • 25. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.
    Gellermann J, Querfeld U.
    Pediatr Nephrol; 2004 Jan; 19(1):101-4. PubMed ID: 14753204
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
    Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L.
    Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
    [Abstract] [Full Text] [Related]

  • 27. New treatment strategies in idiopathic nephrotic syndrome.
    Ulinski T, Aoun B.
    Minerva Pediatr; 2012 Apr; 64(2):135-43. PubMed ID: 22495188
    [Abstract] [Full Text] [Related]

  • 28. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.
    Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, Van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P.
    Pediatr Nephrol; 2009 Aug; 24(8):1525-32. PubMed ID: 19280229
    [Abstract] [Full Text] [Related]

  • 29. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.
    Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, Bandin F, Godron A, Morin D, Brochard K, Gandia P, Bouchet S, Marquet P, Decramer S, Harambat J.
    Clin J Am Soc Nephrol; 2016 Oct 07; 11(10):1777-1782. PubMed ID: 27445161
    [Abstract] [Full Text] [Related]

  • 30. Pediatric idiopathic nephrotic syndrome: treatment strategies in steroid dependent and steroid resistant forms.
    Ulinski T, Aoun B.
    Curr Med Chem; 2010 Oct 07; 17(9):847-53. PubMed ID: 20156172
    [Abstract] [Full Text] [Related]

  • 31. Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children.
    Nickavar A, Safarzadeh AE, Sotoudeh K, Otukesh H, Hooman N.
    Iran J Kidney Dis; 2012 Sep 07; 6(5):346-9. PubMed ID: 22976259
    [Abstract] [Full Text] [Related]

  • 32. Evaluation and management of steroid-sensitive nephrotic syndrome.
    Hodson EM, Alexander SI.
    Curr Opin Pediatr; 2008 Apr 07; 20(2):145-50. PubMed ID: 18332709
    [Abstract] [Full Text] [Related]

  • 33. [Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil].
    Noroña B, Valentín M, Gutiérrez E, Praga M.
    Nefrologia; 2004 Apr 07; 24(1):79-82. PubMed ID: 15083963
    [Abstract] [Full Text] [Related]

  • 34. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome.
    Al-Akash S, Al-Makdama A.
    Ann Saudi Med; 2005 Apr 07; 25(5):380-4. PubMed ID: 16270759
    [Abstract] [Full Text] [Related]

  • 35. Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience.
    Echeverri CV, Valencia GA, Higuita LM, Gayubo AK, Ochoa CL, Rosas LF, Muñoz LC, Sierra J, Zuleta JJ, Ruiz JJ.
    J Bras Nefrol; 2013 Apr 07; 35(3):200-5. PubMed ID: 24100739
    [Abstract] [Full Text] [Related]

  • 36. Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?
    Fujinaga S, Sakuraya K.
    Pediatr Nephrol; 2018 Dec 07; 33(12):2389-2390. PubMed ID: 29959531
    [No Abstract] [Full Text] [Related]

  • 37. Using mycophenolate mofetil in steroid-resistant nephrotic syndrome.
    Ganji MR.
    Iran J Kidney Dis; 2012 Sep 07; 6(5):323-5. PubMed ID: 22976252
    [No Abstract] [Full Text] [Related]

  • 38. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome.
    de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V.
    Pediatr Nephrol; 2010 Mar 07; 25(3):453-60. PubMed ID: 19937060
    [Abstract] [Full Text] [Related]

  • 39. [Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy].
    Takeda Y, Tomino Y.
    Nihon Rinsho; 2004 Oct 07; 62(10):1875-9. PubMed ID: 15500133
    [Abstract] [Full Text] [Related]

  • 40. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study).
    Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, Höcker B, Hoyer PF, Kästner B, Kemper MJ, Konrad M, Luntz S, Querfeld U, Sander A, Toenshoff B, Weber LT, Gesellschaft für Pädiatrische Nephrologie (GPN).
    BMJ Open; 2018 Oct 10; 8(10):e024882. PubMed ID: 30309995
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 8.